Corrections Aesthetic Surgery Journal 2015, Vol 35(5) 631 © 2015 The American Society for Aesthetic Plastic Surgery, Inc.
Erratum Osaki T, Osaki MH, Osaki TH, Sant’Anna AE, Yu MCZ, Hofling-Lima AL. Absence of Bacterial or Fungal Growth in Vials of Reconstituted Botulinum Toxin Type A After Storage. Aesthetic Surg J. 2015; 35(2): 189-193. DOI: 10.1093/asj/sju072 In this article, the author identified errors in the Methods section that were erroneously overlooked during the production process. The corrected paragraphs appear below. The Journal regrets this error. Eighty-eight consecutive 100-U vials of BTXA (onabotulinumtoxinA, Botox; Allergan Inc) were assessed for fungal and/or bacterial contamination according to a protocol approved by the Institutional Review Board of the Federal University of São Paulo. Reconstituted BTX-A was used under aseptic conditions to treat essential blepharospasm or hemifacial spasm patients (group 1: 68 vials) or for facial rejuvenation (group 2: 20 vials). Two of the senior investigators (M.H.O. and A.E.S.) performed all steps involved in preparing and administering the BTX-A. For Group 1, immediately before application, the rubber top of each vial was punctured with a 22-G needle, and the BTX-A preparation was reconstituted with 2.0 mL of normal saline without preservatives. With the 22-G needle attached to the vial, an insulin syringe was connected, and a volume of reconstituted BTX-A was aspirated according to the patient’s clinical condition and
individual response. The insulin syringe then was disconnected from the 22-G needle and attached to a separate insulin needle. Each BTX-A vial was used to treat one patient in group 1. After application, the aspiration needle was withdrawn and each vial was placed in a plastic bag and stored for 4 weeks at 3 to 5°C on shelves of an unlocked, multipurpose medication refrigerator in a clean utility room. For group 2, each BTX-A vial was used to treat two different patients (each patient received a single BTX-A application) for facial rejuvenation in intervals of 0 to 7 days. All applications in this group were also performed under aseptic conditions and by following the same reconstitution steps described above. During the period between applications, the vial with the solution was stored in a sealed plastic container and kept in a refrigerator at 5°C. Before application to the second patient, the metal and rubber caps were removed, in order to aspirate the solution. After aspiration, the vials were recapped with the rubber cap. Upon completion of each vial use, each vial was placed in a plastic bag and stored for 4 weeks at 3°C to 5°C on a shelf of an unlocked, multipurpose medication refrigerator in a clean utility room (same refrigerator used for Group 1). The refrigerator door was opened and closed as needed for routine office practice, and access to the refrigerator for other supplies was not restricted.
DOI: 10.1093/asj/sjv124
Retraction Zhang GL, Meng H, Huang JH, Hong XF, Zhang HS. T-Shaped Excision of the Orbicularis Oris Muscle: An Innovative Technique for Upper Lip Lift Procedures. Aesthetic Surg J. 2015; 35(4): 456-461. DOI: 10.1093/asj/sju056 It has come to our attention that this article contains images (Figure 1, Figure 3, Figure 4) that were duplicates to previously published work in the article: “Application of Upper-lip Lifting Procedure in Perioral Rejuvenation” by
Pan Bailin, Xie Hongbin, Cheng Hong in the Chinese Journal of Medical Aesthetics and Cosmetology, 2015; 21(1):19-22. Permission to reproduce was not sought nor granted and no attribution was included for the use of these figures. For this reason, the publication in the Aesthetic Surgery Journal has been retracted by Foad Nahai, MD, Editor in Chief, Aesthetic Surgery Journal. DOI: 10.1093/asj/sjv123
Erratum Osaki T, Osaki MH, Osaki TH, Sant’Anna AE, Yu MCZ, Hofling-Lima AL. Absence of Bacterial or Fungal Growth in Vials of Reconstituted Botulinum Toxin Type A After Storage. Aesthetic Surg J. 2015; 35(2): 189-193. DOI: 10.1093/asj/sju072 In this article, the author identified errors in the Methods section that were erroneously overlooked during the production process. The corrected paragraphs appear below. The Journal regrets this error. Eighty-eight consecutive 100-U vials of BTXA (onabotulinumtoxinA, Botox; Allergan Inc) were assessed for fungal and/or bacterial contamination according to a protocol approved by the Institutional Review Board of the Federal University of São Paulo. Reconstituted BTX-A was used under aseptic conditions to treat essential blepharospasm or hemifacial spasm patients (group 1: 68 vials) or for facial rejuvenation (group 2: 20 vials). Two of the senior investigators (M.H.O. and A.E.S.) performed all steps involved in preparing and administering the BTX-A. For Group 1, immediately before application, the rubber top of each vial was punctured with a 22-G needle, and the BTX-A preparation was reconstituted with 2.0 mL of normal saline without preservatives. With the 22-G needle attached to the vial, an insulin syringe was connected, and a volume of reconstituted BTX-A was aspirated according to the patient’s clinical condition and
individual response. The insulin syringe then was disconnected from the 22-G needle and attached to a separate insulin needle. Each BTX-A vial was used to treat one patient in group 1. After application, the aspiration needle was withdrawn and each vial was placed in a plastic bag and stored for 4 weeks at 3 to 5°C on shelves of an unlocked, multipurpose medication refrigerator in a clean utility room. For group 2, each BTX-A vial was used to treat two different patients (each patient received a single BTX-A application) for facial rejuvenation in intervals of 0 to 7 days. All applications in this group were also performed under aseptic conditions and by following the same reconstitution steps described above. During the period between applications, the vial with the solution was stored in a sealed plastic container and kept in a refrigerator at 5°C. Before application to the second patient, the metal and rubber caps were removed, in order to aspirate the solution. After aspiration, the vials were recapped with the rubber cap. Upon completion of each vial use, each vial was placed in a plastic bag and stored for 4 weeks at 3°C to 5°C on a shelf of an unlocked, multipurpose medication refrigerator in a clean utility room (same refrigerator used for Group 1). The refrigerator door was opened and closed as needed for routine office practice, and access to the refrigerator for other supplies was not restricted.
DOI: 10.1093/asj/sjv124
Retraction Zhang GL, Meng H, Huang JH, Hong XF, Zhang HS. T-Shaped Excision of the Orbicularis Oris Muscle: An Innovative Technique for Upper Lip Lift Procedures. Aesthetic Surg J. 2015; 35(4): 456-461. DOI: 10.1093/asj/sju056 It has come to our attention that this article contains images (Figure 1, Figure 3, Figure 4) that were duplicates to previously published work in the article: “Application of Upper-lip Lifting Procedure in Perioral Rejuvenation” by
Pan Bailin, Xie Hongbin, Cheng Hong in the Chinese Journal of Medical Aesthetics and Cosmetology, 2015; 21(1):19-22. Permission to reproduce was not sought nor granted and no attribution was included for the use of these figures. For this reason, the publication in the Aesthetic Surgery Journal has been retracted by Foad Nahai, MD, Editor in Chief, Aesthetic Surgery Journal. DOI: 10.1093/asj/sjv123
